Eye Journal
Response to: ‘Comment on The Eye Phone Study: reliability and accuracy of assessing Snellen visual acuity using smartphone technology’ – (Eye 29, 1628 (December 2015))
Response to: ‘Comment on The Eye Phone Study: reliability and accuracy of assessing Snellen visual acuity using smartphone technology’ Eye 29, 1628 (December 2015). doi:10.1038/eye.2015.169 Authors: C Perera & R Chakrabarti
Comment on ‘Failure of intravitreal bevacizumab in the treatment of choroidal metastasis’ – (Eye 29, 1628 (December 2015))
Comment on ‘Failure of intravitreal bevacizumab in the treatment of choroidal metastasis’ Eye 29, 1628 (December 2015). doi:10.1038/eye.2015.174 Authors: H R Kourie, J Antoun & J Kattan
Intravitreal bevacizumab for choroidal metastases: the key to efficacy is simultaneous administration of systemic therapy – (Eye 29, 1629 (December 2015))
Intravitreal bevacizumab for choroidal metastases: the key to efficacy is simultaneous administration of systemic therapy Eye 29, 1629 (December 2015). doi:10.1038/eye.2015.176 Authors: N Singh, R Bansal, D Behera & A Gupta
Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ – (Eye 29, 1630 (December 2015))
Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ Eye 29, 1630 (December 2015). doi:10.1038/eye.2015.190 Author: V P Dave
Annual acknowledgement of manuscript reviewers – (Eye 29, 1517 (December 2015))
Annual acknowledgement of manuscript reviewers Eye 29, 1517 (December 2015). doi:10.1038/eye.2015.229 Author: